Dr Reddys Laboratories informs about press release

19 Apr 2016 Evaluate

Dr Reddys Laboratories has informed about a Press Release dated April 19, 2016 titled ‘ZEMBRACE SymTouch (sumatriptan injection) 3 mg, approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the US’.

The above information is a part of company’s filings submitted to BSE.

Dr. Reddys Lab Share Price

1166.45 -9.10 (-0.77%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×